The EU GMP-produced medical cannabis oral solution has been relaunched by Tilray Brands. The leading cannabis company wants to bring this product to Ireland through the country’s Medicinal Cannabis Access Program (MCAP). Consumers can be confident that the product guarantees access to medical cannabis. If not, it is important to note that the product has reimbursement approval, which offers patients a return on costs.
Tilray seeks to provide eligible patients with access to quality medical cannabis under Ireland’s MCAP. The company believes that the relaunch of this product is essential so that consumers in the European country can enjoy the various benefits of the plant.
Denise Faltischek, Director of Strategy and Head of International Business at Tilray Brands, says she and her team are delighted to have relaunched in Ireland with a much wider footprint. She added, “The MCAP reimbursement approval is a tremendous step in providing patients with greater access to Tilray’s high-quality medical cannabis products that address their needs. We remain dedicated to doing our part to increase access for patients in need around the world.”
Through MCAP, patients in Ireland have access to the full-spectrum medical marijuana oil solution developed by Tilray’s top team. The firm aims to supply Irish patients with a complete package of medical marijuana-based products once local regulations give the go-ahead.
Tilray Medical is a division of Tilray that has been tasked with looking after the health of consumers around the world. After obtaining EU-GMP certification in more than 20 countries, the brand has a portfolio of products ready to provide the best possible quality. Exhaustively selected, each Tilray product seeks to ensure that patients receive consistency and quality when it comes to medical marijuana delivery.